Literature DB >> 2457757

Effects and pharmacokinetics of bolus injections of atrial natriuretic factor in normal volunteers.

J R Cusson1, P Du Souich, P Hamet, E L Schiffrin, O Kuchel, J Tremblay, M Cantin, J Genest, P Larochelle.   

Abstract

The aim of this study was to examine the hemodynamic, renal, and endocrine effects of exogenous human atrial natriuretic factor (ANF), together with its pharmacokinetics, in healthy volunteers. Ten subjects participated in this study, in which the effects of a single bolus dose of ANF and of a matched vehicle injection were compared under a 135 mmol/day sodium intake. Doses of 3, 12.5, and 25 micrograms of ANF were given to 1 subject each, and doses of 50 and 100 micrograms were given to 4 and 3 subjects, respectively. Significantly, hemodynamic changes occurred at the 100 micrograms dose, when mean blood pressure decreased by 15% and heart rate increased reciprocally. Diuresis and natriuresis tended to increase following 50 micrograms but increased significantly and in a prolonged fashion following 100 micrograms of ANF. Atrial natriuretic factor did not cause significant changes in plasma catecholamine, renin activity, and aldosterone levels at any dose, although aldosterone tended to decrease. Plasma arginine-vasopressin concentrations decreased significantly following 100 micrograms. Plasma cyclic GMP levels increased in all subjects and in a dose-dependent fashion. Plasma ANF concentrations peaked 3-5 min following the bolus injection and returned toward baseline values within 10-60 min. Although with doses of less than or equal to 50 micrograms plasma ANF levels increased up to 8 to 50-fold, compared to baseline values, the only significant change was the increase in plasma cyclic GMP levels, perhaps because the effects of ANF were successfully masked by counter-regulatory mechanisms.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457757     DOI: 10.1097/00005344-198806000-00002

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Raised plasma levels of atrial natriuretic factor in cardiac allograft recipients: evidence of increased cardiac secretion and decreased renal clearance.

Authors:  C C Lang; T Moreland; A M Choy; T H Pringle; G P McNeill; A D Struthers
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

2.  Dissociation of natriuresis and diuresis and heterogeneity of the effector system of atrial natriuretic factor in rats.

Authors:  R C Willenbrock; J Tremblay; R Garcia; P Hamet
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

Review 3.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

4.  Human pharmacokinetics of an analogue of atrial natriuretic factor.

Authors:  S H Ingwersen; H Eiskjaer; M Schmiegelow; E B Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Pharmacokinetics and effects of atrial natriuretic factor during hypothermic cardiopulmonary bypass.

Authors:  M Hynynen; K T Olkkola; R Palojoki; I Tikkanen; F Fyhrquist
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

6.  Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.

Authors:  C Gros; A Souque; J C Schwartz; J Duchier; A Cournot; P Baumer; J M Lecomte
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.